MBRX 8-K: SEC filing
Moleculin Biotech
Filed with the SEC on · accession 0001437749-26-036164
MBRX filed a 8-K (current report) with the SEC on Nov 10, 2026. Moleculin Biotech announced new preclinical data showing its lead drug candidate Annamycin (naxtarubicin), when combined with PD-1 immune checkpoint blockade, extended survival in pancreatic cancer models beyond either agent alone. The stock moved -6.9% by the first close after the filing.
Summary of the filing
Moleculin Biotech announced new preclinical data showing its lead drug candidate Annamycin (naxtarubicin), when combined with PD-1 immune checkpoint blockade, extended survival in pancreatic cancer models beyond either agent alone. The findings were presented at the 6th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care.
Key details
How MBRX stock reacted
Close before
$8.66
Nov 9, 2026
First close after
-6.93%
$8.06
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for MBRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for MBRX?
Click hereFrequently asked questions
What did MBRX file with the SEC on Nov 10, 2026?
MBRX filed a 8-K (SEC filing). Moleculin Biotech announced new preclinical data showing its lead drug candidate Annamycin (naxtarubicin), when combined with PD-1 immune checkpoint blockade, extended survival in pancreatic cancer models beyond either agent alone. The findings were presented at the 6th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
How did MBRX stock react to this filing?
MBRX closed at $8.66 before the filing and $8.06 on Nov 10, 2026 (-6.93%).
Other MBRX SEC filings
Get alerts when MBRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days